Oral probiotics potential for the management of dermatological diseases is vast. However, results of available studies in skin diseases, such as atopic dermatitis (AD), are inconsistent, partly because probiotic effects are strain specific. Careful selection of probiotic strains is therefore indispensable to ensure efficacy of treatment. In this study, Lactobacillus salivarius LA307, Lactobacillus rhamnosus LA305 and Bifidobacterium bifidum PI22, three strains that were previously identified for their interesting immunomodulatory properties in allergy and/or colitis models, were assessed in the prevention of chronic skin inflammation induced by repeated applications of 12-O-tetradecanoylphorbol-13-acetate in hairless SKH-1 mice. Macroscopic and microscopic evaluation of skin lesions was performed together with measurements of serum levels of interleukin (IL)-1β, IL-6, tumour necrosis factor alpha (TNF-α), IL-17, IL-22, IL-10 and IL-4. Daily oral treatment with the three strains at the dose of 1×109 cfu/day for 3 weeks limited the development of chronic skin inflammation, the effects being strain dependent. Indeed the two Lactobacillus strains significantly limited the intensity of skin inflammation both at the macroscopic and microscopic levels. Macroscopic observations were correlated to the histological observations and the resulting microscopic score. This limitation of the development of AD-like skin lesions involved the modulation of cytokine production. Treatment with the two Lactobacillus strains induced a decrease in the serum levels of pro-inflammatory cytokines IL-1β, IL-6, TNF-α, IL-17, IL-22 and at the opposite an increase in the production of the anti-inflammatory cytokine IL-10 and also of IL-4. Globally, B. bifidum PI22 had lower benefits. These results obtained in mice suggest that L. salivarius LA307 and L. rhamnosus LA305 could be good candidates for preserving skin integrity and homeostasis via the modulation of the gut microbiota and that their use could be beneficial in dermatological conditions such as AD.
RESEARCH ARTICLE
Lactobacillus salivarius LA307 and Lactobacillus rhamnosus LA305 attenuate skin inflammation in mice
S. Holowacz Related information
1Groupe PiLeJe, 37 Quai de Grenelle, 75015 Paris Cedex 15, France.
*Corresponding author: s. holowacz@pileje. com
, C. Blondeau Related information*Corresponding author: s.
1Groupe PiLeJe, 37 Quai de Grenelle, 75015 Paris Cedex 15, France.
, I. Guinobert Related information1Groupe PiLeJe, 37 Quai de Grenelle, 75015 Paris Cedex 15, France.
, A. Guilbot Related information1Groupe PiLeJe, 37 Quai de Grenelle, 75015 Paris Cedex 15, France.
, S. Hidalgo Related information2Etap-Lab, 13 Rue du Bois de la Champelle, 54500 Vandœuvre-lès-Nancy, France.
, J.F. Bisson Related information2Etap-Lab, 13 Rue du Bois de la Champelle, 54500 Vandœuvre-lès-Nancy, France.
Beneficial Microbes: 9
(2)- Pages: 299 - 309
Published Online: February 07, 2018
Abstract
Keywords: probiotics, prevention, skin inflammation, atopic dermatitis, cytokine
2022 Journal Impact Factor
5.4
source: Journal Impact Factor 2023™ from Clarivate™
Institutional Offers
For institutional orders, please contact [email protected].
-
A.A. Hibberd, C.C. Yde, M.L. Ziegler, A.H. Honoré, M.T. Saarinen, S. Lahtinen, B. Stahl, H.M. Jensen and L.K. Stenman
-
E.E. Blaak, E.E. Canfora, S. Theis, G. Frost, A.K. Groen, G. Mithieux, A. Nauta, K. Scott, B. Stahl, J. van Harsselaar, R. van Tol, E.E. Vaughan and K. Verbeke
-
K. Venema, J. Verhoeven, C. Beckman and D. Keller
-
E. Arvidsson Nordström, C. Teixeira, C. Montelius, B. Jeppsson and N. Larsson
-
J.E. Haarhuis, A. Kardinaal and G.A.M. Kortman
-
E.E. Blaak, E.E. Canfora, S. Theis, G. Frost, A.K. Groen, G. Mithieux, A. Nauta, K. Scott, B. Stahl, J. van Harsselaar, R. van Tol, E.E. Vaughan and K. Verbeke
-
K. Lippert, L. Kedenko, L. Antonielli, I. Kedenko, C. Gemeier, M. Leitner, A. Kautzky-Willer, B. Paulweber and E. Hackl
-
K. Tsilingiri and M. Rescigno
-
M. Ozen and E.C. Dinleyici
-
Y. Kobayashi, T. Kuhara, M. Oki and J.-Z. Xiao